ProCE Banner Activity

A Year in Review: ADCs Targeting HER3 in NSCLC

Slideset

Gain expert insights with these downloadable slides featuring key data on HER3-directed antibody–drug conjugates and implications for management of advanced EGFR-mutated NSCLC with resistance to EGFR TKI therapy.

Released: January 29, 2024

Share

Faculty

Helena Yu

Helena Yu, MD

Associate Attending
Research Director of Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.